', 'auto', 'clientTracker'); ga('clientTracker.send', 'pageview');
Oct 26, 2020
Renee Ryan is the CEO and Dr. Kate Roosenbluth is the founder, CSO, and member of the board of directors for Cala Health. The company creates bioelectronic neuromodulation devices to mitigate the effects of chronic diseases. In this episode, Renee Ryan and Dr. Kate Rosenbluth discuss how the Cala Trio device controls essential tremors.
Top three takeaways:
[0:00] Ladan introduces the episode and the guests, Renee Ryan and Dr. Kate Rosenbluth.
[4:50] Dr. Kate Rosenbluth explains the history of the company and its goals.
[7:00] The wearable device goes on the user’s wrist to stimulate the ventral intermediate nucleus in the brain.
[9:00] The essential tremors are characterized by action tremors in the hands, which makes daily tasks incredibly difficult.
[13:40] Cala Health plans to accomplish more wrist-based projects to help mitigate other chronic diseases.
[16:30] Renee Ryan explains her transition from investor to CEO at Cala Health.
[19:30] The demand for the Cala Trio device was so great that the clinical trials were fully enrolled within 6 weeks.
[22:30] Due to the wristband having dry electrodes, the band needs to be replaced every 90 days.
[25:20] A new device trial has started that includes a new band technology.